Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study
Publication
, Conference
Schoenbeck, K; Clements, J; Demairo, K; Wei, D; Hazra, NC; Constantinescu, C; Meng, Y; Latremouille-Viau, D; Jadhav, K; McDermott, C; Yang, D ...
Published in: Blood
November 5, 2024
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 5, 2024
Volume
144
Issue
Supplement 1
Start / End Page
7913 / 7913
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Schoenbeck, K., Clements, J., Demairo, K., Wei, D., Hazra, N. C., Constantinescu, C., … Flynn, K. E. (2024). Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study. In Blood (Vol. 144, pp. 7913–7913). American Society of Hematology. https://doi.org/10.1182/blood-2024-207213
Schoenbeck, Kelly, Joan Clements, Karen Demairo, David Wei, Nisha C. Hazra, Cristina Constantinescu, Yan Meng, et al. “Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study.” In Blood, 144:7913–7913. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-207213.
Schoenbeck K, Clements J, Demairo K, Wei D, Hazra NC, Constantinescu C, et al. Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study. In: Blood. American Society of Hematology; 2024. p. 7913–7913.
Schoenbeck, Kelly, et al. “Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 7913–7913. Crossref, doi:10.1182/blood-2024-207213.
Schoenbeck K, Clements J, Demairo K, Wei D, Hazra NC, Constantinescu C, Meng Y, Latremouille-Viau D, Jadhav K, McDermott C, Yang D, Damon A, Sadek I, Guerin A, Flynn KE. Impact of Adverse Events on Health-Related Quality of Life in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs) - Early Results of the Survey on Humanistic Burden of Intolerance to First or Second TKIs (SHIFT) Study. Blood. American Society of Hematology; 2024. p. 7913–7913.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 5, 2024
Volume
144
Issue
Supplement 1
Start / End Page
7913 / 7913
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology